Hyperhomocysteinemie als risicofactor voor veneuze trombose

H. P.J. Willems; M. Den Heijer; H. J. Blom; W. B.J. Gerrits; F. R. Rosendaal; G. M.J. Bos

Hyperhomocysteinemie als risicofactor voor veneuze trombose

Translated title of the contribution: Hyperhomocysteinaemia, a risk factor for venous thrombosis

H. P.J. Willems, M. Den Heijer, H. J. Blom, W. B.J. Gerrits, F. R. Rosendaal, G. M.J. Bos

Internal Medicine (VUmc)

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

Abstract

In recent years research was done to elucidate the relation between an increased homocysteine concentration and arterial as well as venous thrombosis. Several case control studies showed that an elevated homocysteine concentration is an independent risk factor for primary and secundary venous thromboembolism. It is not clear whether lowering homocysteine levels by administration of folic acid, whether or not in combination with vitamin B₁₂ and vitamin B₆, decreases the risk of vascular events. Randomized secondary prevention trials are being conducted at this moment. It is recommended to await the results of these trials before screening for and treating of individuals with hyperhomocysteinaemia.

Translated title of the contribution	Hyperhomocysteinaemia, a risk factor for venous thrombosis
Original language	Dutch
Pages (from-to)	552-556
Number of pages	5
Journal	Nederlands Tijdschrift voor Geneeskunde
Volume	143
Issue number	11
Publication status	Published - 13 Mar 1999

Cite this

@article{92f492575125450ba9f8cd67c026498a,

title = "Hyperhomocysteinemie als risicofactor voor veneuze trombose",

abstract = "In recent years research was done to elucidate the relation between an increased homocysteine concentration and arterial as well as venous thrombosis. Several case control studies showed that an elevated homocysteine concentration is an independent risk factor for primary and secundary venous thromboembolism. It is not clear whether lowering homocysteine levels by administration of folic acid, whether or not in combination with vitamin B12 and vitamin B6, decreases the risk of vascular events. Randomized secondary prevention trials are being conducted at this moment. It is recommended to await the results of these trials before screening for and treating of individuals with hyperhomocysteinaemia.",

author = "Willems, {H. P.J.} and {Den Heijer}, M. and Blom, {H. J.} and Gerrits, {W. B.J.} and Rosendaal, {F. R.} and Bos, {G. M.J.}",

year = "1999",

month = mar,

day = "13",

language = "Dutch",

volume = "143",

pages = "552--556",

journal = "Nederlands Tijdschrift voor Geneeskunde",

issn = "0028-2162",

publisher = "Vereniging Nederlands Tijdschrift voor Geneeskunde",

number = "11",

}

TY - JOUR

T1 - Hyperhomocysteinemie als risicofactor voor veneuze trombose

AU - Willems, H. P.J.

AU - Den Heijer, M.

AU - Blom, H. J.

AU - Gerrits, W. B.J.

AU - Rosendaal, F. R.

AU - Bos, G. M.J.

PY - 1999/3/13

Y1 - 1999/3/13

N2 - In recent years research was done to elucidate the relation between an increased homocysteine concentration and arterial as well as venous thrombosis. Several case control studies showed that an elevated homocysteine concentration is an independent risk factor for primary and secundary venous thromboembolism. It is not clear whether lowering homocysteine levels by administration of folic acid, whether or not in combination with vitamin B12 and vitamin B6, decreases the risk of vascular events. Randomized secondary prevention trials are being conducted at this moment. It is recommended to await the results of these trials before screening for and treating of individuals with hyperhomocysteinaemia.

AB - In recent years research was done to elucidate the relation between an increased homocysteine concentration and arterial as well as venous thrombosis. Several case control studies showed that an elevated homocysteine concentration is an independent risk factor for primary and secundary venous thromboembolism. It is not clear whether lowering homocysteine levels by administration of folic acid, whether or not in combination with vitamin B12 and vitamin B6, decreases the risk of vascular events. Randomized secondary prevention trials are being conducted at this moment. It is recommended to await the results of these trials before screening for and treating of individuals with hyperhomocysteinaemia.

UR - http://www.scopus.com/inward/record.url?scp=0033550830&partnerID=8YFLogxK

M3 - Article

C2 - 10321272

SN - 0028-2162

VL - 143

SP - 552

EP - 556

JO - Nederlands Tijdschrift voor Geneeskunde

JF - Nederlands Tijdschrift voor Geneeskunde

IS - 11

ER -

Hyperhomocysteinemie als risicofactor voor veneuze trombose

Abstract

Other files and links

Cite this